Caspases, a family of cysteine proteases, are major mediators of apoptosis and inflammation. Caspase-6 is classified as an apoptotic effector, and it mediates nuclear shrinkage during apoptosis, but it possesses unique activation and regulation mechanisms that differ from those of other effector caspases. Furthermore, increasing evidence has shown that caspase-6 is highly involved in axon degeneration and neurodegenerative diseases, such as Huntington's disease and Alzheimer's disease. Cleavage at the caspase-6 site in mutated huntingtin protein is a prerequisite for the development of the characteristic behavioral and neuropathological features of Huntington's disease. Active caspase-6 is present in early stages of Alzheimer's disease, and caspase-6 activity is associated with the disease's pathological lesions. In this review, we discuss the evidence relevant to the role of caspase-6 in neurodegenerative diseases and summarize its activation and regulation mechanisms. In doing so, we provide new insight about potential therapeutic approaches that incorporate the modulation of caspase-6 function for the treatment of neurodegenerative diseases. 
INTRODUCTION
Caspases, a family of cysteine proteases that cleave substrates after an aspartate residue, are major mediators of apoptosis and inflammation (1) (2) (3) . Caspases can be divided into three groups on the basis of their function and sequence similarities: (a) inflammatory caspases, (b) apoptotic initiators, and (c) apoptotic effectors. All caspases are produced as catalytically inactive zymogens in cells and must undergo proteolytic activation during apoptosis. Apoptotic initiators undergo induced proximity activation, after which they process and activate apoptotic effectors (1) (2) (3) . Caspase-6, along with caspase-3 and caspase-7, is classified as an apoptotic effector. The gene encoding caspase-6 is Mch2 in humans (4) , and caspase-6 is often activated by caspase-3 rather than by initiator caspases during apoptosis (5, 6) . However, caspase-6 activation is also observed in the absence of caspase-3 activity (7) (8) (9) , and caspase-6 can undergo autoactivation in vitro and in vivo (10, 11) .
During apoptosis, caspase-6 localizes in the nucleus, cleaves the nuclear structural protein NuMA (nuclear mitotic apparatus protein) (6) and the lamin proteins (12) , and induces nuclear shrinkage and fragmentation. Furthermore, many transcription factors are substrates of caspase-6, including nuclear factor κB (NF-κB), special AT-rich sequence-binding protein 1 (SATB1), activating protein 2α (AP-2α), and CREB-binding protein (CBP) (13) (14) (15) (16) . However, unlike the activity of caspase-3 and caspase-7, caspase-6 activity does not always induce apoptosis. In HEK293 cells, the overexpression of caspase-6 results in high caspase-6 activity in the absence of cell death (10) . Caspase-6 activity localizes to the cytoplasm and neurites of Alzheimer's disease (AD) neurons without exhibiting the classical features of apoptosis (17) .
Caspase-6 is widely expressed in the brain and peripheral tissues (17) (18) (19) (20) (21) . In addition to being involved in apoptosis, caspase-6 is highly involved in axon pruning during development (22) (23) (24) (25) and in adult brains (26) ; pathological axonal degeneration (27) (28) (29) ; and neurodegenerative diseases such as Huntington's disease (HD) (19, (30) (31) (32) (33) (34) and AD (17, 18, (35) (36) (37) (38) (39) (40) (41) ). Caspase-6 knockout (Casp6 −/− ) neurons are protected against excitotoxicity, trophic factor deprivation, and myelininduced axonal degeneration, and caspase-6-deficient mice show an age-dependent increase in cortical and striatal volume and also display a hypoactive phenotype and learning deficits (29) .
Recent structural and biochemical studies have disclosed the activation and regulation mechanisms of caspase-6, including intramolecular self-cleavage (11) , phosphorylation-mediated inhibition (42, 43) , and the function of the prodomain (44). In this review, we summarize evidence regarding the role of caspase-6 in neurodegenerative diseases, describe its activation and regulation mechanisms, discuss the current knowledge about its natural and synthetic inhibitors, and discuss potential therapeutic approaches that incorporate the modulation of caspase-6 function for the treatment of neurodegenerative diseases.
CASPASE-6 IN HUNTINGTON'S DISEASE
HD is a devastating inherited neurodegenerative disease characterized by progressive motor, cognitive, and psychiatric symptoms (45). It is caused by an expansion of a CAG repeat encoding glutamine in the N terminus of huntingtin (Htt) (46). A normal Htt gene (also known as IT15) has fewer than 36 CAG repeats, whereas an abnormal gene has 36 or more repeats. Hereafter, the normal huntingtin protein is referred to as Htt, whereas the abnormal one is referred to as mHtt. In HD, neurodegeneration occurs initially and most severely in the medium-spiny neurons of the striatum, and later in the deep layers of the cortex (45).
The Htt protein is ubiquitously expressed within and outside the nervous system (47), and it is also widely distributed in the subcellular compartments (48-50). A variety of proteins involved in endocytosis, apoptosis, vesicle transport, cell signaling, morphogenesis, and transcriptional QADSVDLASCDLTSSATDGDEEDILSHSSSQVSAVPSDPAMDLNDGTQASSPISDSSQTTTEGPDSAVTPSDSSEIVLDGTDNQY   513  552  586   PEST1   124  412 421  745  1176 1289  1710  2175  3107   PEST3   CASP3  CASP3  CASP6   PEST4   N  C  H1  HEAT2  HEAT3 HEAT4 P PEST2 PEST2
Figure 1
Schematic diagram of huntingtin (Htt). The predicted HEAT domains and PEST sequences are marked along the length of Htt. The HEAT repeats are named for the proteins where they were first described: huntingtin, elongation factor 3 (EF3), protein phosphatase 2A (PP2A), and the yeast kinase TOR. PEST sequences represent polypeptide sequences enriched in proline (P), glutamic acid (E), serine (S), and threonine (T). The caspase-3 (CASP3) and caspase-6 (CASP6) cleavage sites and the primary phosphorylation site (P, yellow) are labeled.
regulation interact with Htt, and Htt acts as a scaffold that brings its interaction partners together to promote the transfer of information among them (51). In addition, Htt increases the production of brain-derived neurotrophic factor (BDNF), a trophic factor for striatal neurons (52). The human Htt protein has a molecular mass of 350 kDa and possesses 3,144 amino acids; it is predominantly composed of HEAT repeats that are clustered into four major HEAT domains; and it contains four PEST sequences (34, 53) (Figure 1) . [The HEAT repeats are named for the proteins where they were first described: huntingtin, elongation factor 3 (EF3), protein phosphatase 2A (PP2A), and the yeast kinase TOR. PEST derives its name from proline (P), glutamic acid (E), serine (S), and threonine (T).] Considerable insight into HD pathogenesis has arisen from the generation of transgenic mouse models. Mouse models of HD fall into three groups according to how they were genetically constructed: N-terminal transgenic mice, full-length transgenic mice, and knockin mice (54, 55). In both N-terminal and full-length transgenic mice, the truncated or full-length mHtt gene is inserted into the mouse genome, resulting in the expression of a mHtt protein in addition to the endogenous normal Htt. The N-terminal transgenic mice, which express a small N-terminal portion of human or mouse mHtt, include models R6/2, R6/1, and N171-82Q. The full-length transgenic mice, which express full-length human mHtt in the form of either YAC (yeast artificial chromosome) or BAC (bacterial artificial chromosome) DNA, include models YAC72, YAC128, and BACHD. The knockin mice are generated through the introduction of a pathological length CAG repeat into the mouse Hdh gene (encoding mouse Htt), leading to either homozygotes or heterozygotes for the mutation. However, the phenotypes of these three mouse models can be significantly different (the differences are well reviewed in Reference 55); therefore, careful attention must be paid when interpreting and comparing data from different models. Furthermore, two factors also influence HD symptoms: the expression level of mHtt and the size of the CAG repeat (56).
Htt: DSVD 513 and DLND 552 for caspase-3, and IVLD 586 for caspase-6 (57, 58). All these caspases sites are located at the PEST2 sequence (Figure 1) . The N-terminal mHtt fragments are toxic in vitro and in vivo (59, 60) , and the accumulation of the N-terminal fragments is observed in postmortem brain from HD subjects and mouse models (61) .
In 2006, Graham and coworkers (30) reported that cleavage of mHtt at the caspase-6 site (IVLD 586 ) was a prerequisite for neuronal dysfunction and degeneration in HD. Since then, increasing evidence has confirmed that cleavage at the caspase-6 site is a critical event in the development of HD. Mice expressing full-length mHtt (YAC128) resistant to caspase-6 cleavage (C6R-mHtt) maintain normal neuronal function and do not develop striatal neurodegeneration (30) or behavioral disturbances (32) . Furthermore, C6R-mHtt mice are also resistant to N-methyl-D-aspartate receptor (NMDAR)-mediated excitotoxicity (30, 33) , which is implicated in the pathogenesis of HD (33) .
Active caspase-6 is present in the brains of presymptomatic and early-grade human HD patients and in those of murine HD models (19) . Active caspase-6 levels correlate directly with CAG size and inversely with age of onset in human HD. In contrast, C6R-mHtt mice attenuate caspase-6 activation (19), suggesting two things: (a) that the mHtt 586 fragment (the N-terminal fragment of mHtt cleaved at IVLD 586 ) may be part of a positive feedback cycle of caspase-6 activation in HD and (b) that specific mHtt fragments may be required to initiate a toxic cycle that leads to the neuropathological abnormalities in HD.
Cleavage of Htt by caspase-6 at IVLD 586 has been confirmed in vitro (30, 34, 57 ), but whether caspase-6 is responsible for the cleavage at this site in vivo is still debatable. A recent study showed that the mHtt 586 fragment was detected in caspase-6-knockout BACHD mice [a bacterial artificial chromosome (BAC)-mediated full-length mHtt transgenic mouse model with caspase-6 being knocked out, BACHD Casp6 −/− ] (62), indicating that caspase-6 activity cannot fully account for the generation of the mHtt 586 fragment in vivo. Nevertheless, it is also possible that complete caspase-6 knockout leads to some compensatory pathway, so analysis of a conditional Casp6 −/− HD mouse model is required to further determine if caspase-6 is the primary protease that cleaves mHtt at IVLD 586 .
Activated Caspase-6 and Caspase-6-Cleaved Huntingtin Fragments Specifically Colocalize in the Nucleus
The nuclear translocation of mHtt and the formation of inclusions are neuropathological hallmarks of HD, and preventing or delaying the nuclear accumulation of mHtt is protective in disease models (63) (64) (65) . In vitro experiments suggest that the nuclear localization of huntingtinrather than the aggregate formation of it-leads to toxicity (66, 67) . In the YAC128 mouse, both the nuclear localization of mHtt and the neuropathology coincidently occur earliest and to the greatest extent in the lateral striatum (65, 68) . In contrast, the nuclear accumulation of mHtt is significantly reduced and delayed in C6R-mHtt YAC128 mice, which are protected from the toxic effects of mHtt (30) . Warby and coworkers (34) showed that the endogenous mHtt 586 fragment was enriched in the nucleus of immortalized striatal cells and primary striatal neurons, where it colocalized with active caspase-6. Moreover, cell stress induced by staurosporine (a general kinase inhibitor used to induce cell death and to activate caspases) results in the nuclear translocation and activation of caspase-6 and an increase in the mHtt 586 fragment in the nucleus (34) . In contrast, the endogenous caspase-2/caspase-3-generated mHtt 552 fragment localizes to the perinuclear region (34) . These findings provide a possible explanation for why the toxicity of mHtt is specifically associated with the mHtt 586 fragment. In addition, treatment with nocodazole (an antineoplastic agent interfering with the polymerization of microtubules) significantly reduces the intensity of active caspase-6 staining in the nucleus, suggesting that the translocation of caspase-6 is important to its activation (34) . Compared with the full-length transgenic mouse model YAC128, an N-terminal transgenic mouse model expressing the mHtt 586 fragment (N586-82Q) shows large cytoplasmic inclusion bodies, which are composed largely of a much smaller mHtt fragment (69, 70) . Although the N586-82Q mice develop more severe neurological abnormalities than do current full-length mHtt models, they may not accurately reflect the specific pathological processes of HD because these precleaved truncated fragments may not enter the correct cellular pathways.
Our knowledge about how Htt fragments are transported into and out of the nucleus remains incomplete. Htt features a cytoplasmic retention signal at the N terminus and a nuclear export signal at the C terminus, both of which could undergo posttranslational modification and thus change the subcellular localization of Htt (53). Phosphorylation at Ser421 reduces the nuclear accumulation of Htt 586 fragment by reducing the level and nuclear localization of full-length Htt and the cleavage of Htt by caspase-6 (71). In addition, Htt's binding partners can also assist in its transport (72) . Regulating the nuclear translocation of mHtt or caspase-6 could be a viable therapeutic strategy to treat HD.
CASPASE-6 IN ALZHEIMER'S DISEASE
AD is a progressive neurodegenerative disorder characterized by global cognitive decline involving memory, orientation, judgment, and reasoning and is the most common form of dementia in the elderly (73) . The formation of extracellular senile plaques and the intraneuronal accumulation of neurofibrillary tangles (NFTs) are two major characteristics of AD. The extracellular plaques are mainly deposits of amyloid-β peptide (Aβ) aggregates, and the NFTs are composed of fibrillar aggregates of hyperphosphorylated tau. Tau is a natively unfolded microtubule-associated protein and might be involved in the assembly and stabilization of microtubules (74) . Plaques and tangles are present mainly in the entorhinal cortex, hippocampus, basal forebrain, and amygdala. Synaptic and neuronal loss is also a major feature of AD (75) . The temporal and frontal lobes of AD patients are reduced in size as the result of synapse degeneration and neuron death (76) .
The pathogenesis of AD remains unclear. There are two main hypotheses for AD pathology, the amyloid and tau hypotheses, and debates between scientists supporting these two hypotheses have lasted for more than 25 years (77) . The amyloid hypothesis states that overproduction of Aβ is the initial insult and leads to NFT pathology along with neuron dysfunction and cell loss. This hypothesis is supported by genetic studies and experimental evidence (73) . Aβ, especially the oligomeric soluble form, induces synaptic degeneration and can be toxic to primary neurons in culture (78) . The tau hypothesis argues that the NFTs correlate better with cognitive impairment and dementia severity than do amyloid levels; therefore, tau hyperphosphorylation and aggregation may be more relevant to AD pathology than amyloid is (79) . However, identifying events that occur before the accumulation of NFTs and Aβ in AD brains will be crucial for the development of AD therapies, and caspase activation, especially activation of caspase-6, has begun to draw considerable attention in recent years.
Activation of Caspase-6 in Alzheimer's Disease
In AD, the level of dementia correlates best with loss of synapses, followed by NFTs, and then amyloid deposit (80) . Both amyloid plaques and NFTs can contribute to the pathophysiology of AD, but elimination of the plaques and tangles may not be able to prevent neuronal dysfunction because the degenerative pathways involved in the formation of plaques and tangles would still be www.annualreviews.org • Caspase-6 Activation and Regulationactivated (80) . Therefore, identifying the degenerative pathways that cause plaques and tangles is crucial.
Caspase-6 activity is associated with AD pathological lesions and is present at the early stages of tangle formation (17, 18) . The proapoptotic protein p53 is increased in AD brains (81) , and p53 directly upregulates the transcription of caspase-6 (82), resulting in a significant increase in caspase-6 mRNA in postmortem brain samples from AD subjects compared with controls (83). Guo and coworkers (17) developed two neo-epitope antisera that recognize active caspase-6 and caspase-6-cleaved tau (Tau Casp6), but do not recognize the inactive or uncleaved forms, in AD brains. Using the two antisera, they showed that active caspase-6 increases 2-to 3-fold in the temporal and frontal cortices of AD patients compared with the non-AD controls and that both active caspase-6 and Tau Casp6 are present in the NFTs, neuropil threads, and neuritic plaques. Furthermore, strong immune staining with both the active caspase-6 and Tau Casp6 antisera is found in the hippocampus and cortex of brains from mild, moderate, severe, and very severe cases of sporadic AD (18) . In addition, Tau Casp6 inversely correlates with global cognitive scores in individuals within the normal cognitive range (18) and also correlates with AD severity (84) . Moreover, caspase-6 activation is also abundant in brains from familial AD with amyloid precursor protein (APP), presenilin I, or presenilin II mutations (85) . The presence of active caspase-6 in both sporadic and familial AD suggests that caspase-6 plays a fundamental role in the pathophysiology of AD.
As mentioned above, caspase-6 activity does not always induce apoptosis. In contrast to the nuclear localization of the enzyme during apoptosis, in AD neurons, caspase-6 activity localizes to the cytoplasm and neurites without inducing apoptosis (18) . In a proteomic analysis of caspase-6-mediated cleavage of human neuronal proteins, α-tubulin, α-actinin-4, spinophilin, and drebrin were confirmed to be direct substrates of caspase-6 (86). Caspase-6 cleaves α-tubulin at Asp438 (86), the same site cleaved by granzyme B in cytotoxic T lymphocytes and natural killer cells. The processing of α-tubulin at this site increases the rate of microtubule polymerization (87). In addition, the level of drebrin is known to decrease in AD (88) . The results of this proteomic analysis (86) imply that the early and neuritic activation of caspase-6 in AD could disrupt the cytoskeleton network of neurons and result in impaired synaptic plasticity or function in the absence of cell death.
Caspase-6 also cleaves valosin-containing protein (VCP/p97), which is a ubiquitin-dependent ATPase that plays a central role in protein degradation pathways mediated by the ubiquitin proteasome system (89) . Cleavage of VCP/p97 by caspase-6 disrupts the ubiquitin-proteasome degradation of misfolded proteins, which may account for the accumulation of ubiquitinated misfolded proteins in AD. Similarly, in a BACHD Casp6
−/− mouse model (a BAC-mediated full-length mHtt transgenic mouse model with caspase-6 knocked out, as mentioned above), both full-length mHtt and fragments are significantly decreased, suggesting a role for caspase-6 activity in the clearance pathways for the mHtt protein (62) .
Cleavage of Amyloid Precursor Protein at Asp664 (a Caspase-6 Site) Is a Prerequisite for Alzheimer's Disease Pathology
Aβ is generated by the proteolytic processing of APP. APP is widely expressed in cells throughout the body, and although the normal function of APP is not fully understood, evidence suggests that it is involved in regulating neuronal survival, neurite outgrowth, synaptic plasticity, and cell adhesion (90) . APP is an integral membrane protein with a single transmembrane domain, a large extracellular glycosylated N terminus, and a shorter cytoplasmic C terminus. Aβ is located at the cell surface, with part of the peptide embedded in the membrane (Figure 2) . APP is produced Alternative processing of amyloid precursor protein (APP). APP is cleaved by α-secretase, releasing the secreted extracellular domain of APP, sAPPα. Alternatively, APP is cleaved by β-secretase (BACE), γ-secretase, and caspase, generating sAPPβ, amyloid-β peptide (Aβ), Jcasp, and C31.
in several different isoforms; the most abundant form in the brain is APP695, which is produced mainly by neurons (76) .
APP is cleaved by α-secretase, releasing the secreted extracellular domain of APP, sAPPα (Figure 2) , which acts as a growth factor for many types of cells and promotes neuritogenesis in postmitotic neurons (90) . Alternatively, the proteolytic processing of APP by β-secretase (BACE), γ-secretase, and caspases generates four proapoptotic peptides: sAPPβ, Aβ, Jcasp, and C31 (91) . Aβ has been considered the central mediator of AD for nearly 30 years (73); however, C31, the C-terminal peptide of APP released by caspase cleavage, has drawn increasing attention because of its cytotoxicity. The caspase site in APP is VEVD 664 (according to APP695 numbering), which is defined as a caspase-6 cleavage site by its sequence (92) , and cleavage at this site by caspase-6 in vitro has been confirmed by different groups (9, 37, 93) . Other caspases such as caspase-3 and caspase-8 have also been shown to be capable of cleaving APP at Asp664 (35, 93) .
The crucial role of cleavage at Asp664 in the development of AD has been confirmed in AD brains, cell culture models, and transgenic mouse models (the studies are well reviewed in Reference 94). Compared with age-matched non-AD controls, AD brains show a significant increase in caspase cleavage of APP at Asp664, which occurs predominantly in the hippocampus and cortex (38, 95). The caspase-generated C31 peptide is a potent inducer of apoptosis in cultured neuroblastoma cells (37). C31 can directly activate a classical apoptotic pathway through an N-terminal Smac/DIABLO-like motif, which binds and antagonizes the family of inhibitor of apoptosis proteins (IAPs) (96) . In addition, C31-mediated cytotoxicity depends on its interaction with APP itself; thus, the toxicity is abolished in the absence of endogenous APP (97) .
D664A mutation in human APP transgenic mice prevents AD-like pathology-including synaptic loss, astrogliosis, dentate gyral atrophy, increased neuronal precursor proliferation, and behavioral abnormalities-without altering Aβ production and plaque formation (39, 41). The mutation also provides long-term prevention of AD-like behavioral deficits in PDAPP mice (98) . Furthermore, the reversal of learning deficits in the D664A mice required early experience, suggesting that the caspase-site mutant rescued retention more than learning itself (99) . Moreover, systemic caspase inhibition by Q-VD-OPh reduced caspase-related pathology without affecting Aβ production in AD mice (100). Interestingly, p21-activated kinase (PAK) signaling also requires C-terminal cleavage of APP at Asp664 (40). PAK interacts with the cytoplasmic domain of APP (101) , and PAK signaling is involved in the pathophysiology of AD (102) .
THE ACTIVATION AND REGULATION MECHANISM OF CASPASE-6
Numerous findings implicate caspase-6 in neurodegenerative diseases, but the activation pathway leading to aberrant caspase-6 activity is unknown, and this uncertainty highlights the need for a deeper understanding of the mechanisms that regulate caspase-6 activation and activity. Caspase-6 has a short prodomain and shares 41% and 37% sequence identity with effectors caspase-3 and caspase-7, respectively; thus, it is classified as an effector caspase. However, caspase-6 has several unique features. First, the substrate specificity of caspase-6 is different from that of caspase-3 and caspase-7 but similar to that of the initiators caspase-8 and caspase-9 (92). Second, IAPs, which inhibit caspase-3, caspase-7, and caspase-9, do not inhibit caspase-6 (103). Third, caspase-6 undergoes self-processing and activation in vitro and in vivo, and high caspase-6 activity does not induce apoptosis in HEK293 cells (10) . Fourth, caspase-6 has a low zymogenicity (ratio of activity of the cleaved form compared with the uncleaved form) of 200 (10), which is comparable with the zymogenicities of initiators caspase-8 (∼100) and caspase-9 (∼10) and much lower than that of caspase-3 (>10,000) (3). In other words, like the initiator caspase zymogens, the caspase-6 zymogen already has low activity without cleavage between the large and small subunits, whereas the caspase-3 zymogen has essentially no activity. Finally, although caspase-6 is an effector, it can act on the initiator caspases to cleave initiators caspase-2 and caspase-8 (5, 104, 105) and induce mitochondrial permeabilization, leading to cytochrome c release and activation of effector caspases (7). Structural and mechanistic studies have revealed the reason why caspase-6 is such a unique effector caspase.
Autoactivation Mechanism of Caspase-6 and the Function of the Prodomain
Caspase-6 is expressed as a dimeric zymogen composed of a short prodomain, a large subunit (p20), an intersubunit linker, and a small subunit (p10). The three cleavage sites of caspase-6 are the residues TETD 23 after the prodomain and DVVD 179 and TEVD 193 in the intersubunit linker (Figure 3a) . Activation of effector caspases requires cleavage in the intersubunit linker to release the N terminus of p10, which rotates approximately 180
• to form the so-called loop bundle with the four loops of the adjacent catalytic unit and which stabilizes the substrate binding pockets (106) . Cleavage at either or both of the two intersubunit cleavage sites is sufficient for caspase-6 activation, and the prodomain inhibits autoactivation of caspase-6 in vivo but not in vitro (10) . Caspase-6 can either undergo autoactivation (10, 11) or be activated by caspase-3 (5, 25); however, the activation patterns of autoactivation and activation by caspase-3 are different. During autoactivation, caspase-6 loses its prodomain first (undergoing cleavage at TETD 23 ) , then cleaves at TEVD 193 , and undergoes its final cleavage at DVVD 179 . In contrast, caspase-3 cleaves caspase-6 at DVVD 179 first, and then at TETD 23 and TEVD 193 . Caspase-6 zymogen structures show that the intersubunit cleavage site, TEVD 193 , binds to the active site of the same catalytic unit (11, 42, 44, 107) (Figure 3b) . This cleavage site-bound conformation is unique to caspase-6 because of its long intersubunit linker, and the linkers of caspase-3 and caspase-7 are too short to place their intersubunit cleavage sites in their own active sites (11) . On the basis of the caspase-6 zymogen structure and the observation that caspase-6 undergoes autoactivation in vitro and in vivo in the absence of other caspases (10), we proposed the intramolecular self-cleavage (cleavage occurs within one molecule) mechanism for caspase-6 (11). The intramolecular cleavage at the TEVD 193 site is essential for initiating caspase-6 activation in the absence of caspase-3, but intermolecular cleavage (cleavage by another molecule of the same kind) at this site also contributes to the autoactivation once active caspase-6 is generated.
The prodomain somehow inhibits the intramolecular cleavage of caspase-6 at the TEVD 193 site, but the mechanism is unclear (44). Meanwhile, although the sequence of the TETD 23 cleavage site is similar to that of the TEVD 193 site, TETD 23 is always cleaved before TEVD 193 during intermolecular self-cleavage, indicating that the TETD 23 site is always more available for cleavage. This cleavage priority of the TETD 23 site makes the prodomain act as a "suicide protector," which protects the TEVD 193 site from intermolecular self-cleavage as well (44). This "suicide protection" can be effective when the protein concentration is low, as it is in vivo. Thus, the suicide protection explains why the prodomain can inhibit caspase-6 autoactivation in vivo but not in vitro.
Phosphorylation Inhibits Caspase-6 Activation and Activity Through Two Different Mechanisms
Caspase-6 is negatively regulated by phosphorylation at Ser257 mediated by AMP-activated protein kinase (AMPK)-related kinase 5 (ARK5, also known as NUAK1). Phosphorylation at Ser257 inhibits autoactivation of caspase-6 in vitro and in vivo and also suppresses the caspase-3-processed caspase-6 (108). Structural studies of pseudophosphorylated caspase-6 mutants reveal the mechanism of phosphorylation-mediated inhibition (42, 43). Phosphorylation inhibits autoactivation of caspase-6 by locking caspase-6 in the TEVD 193 -bound state (42), which prevents the cleavage at TEVD 193 (Figure 3c) . Meanwhile, if caspase-6 is activated by caspase-3, phosphorylation will still inhibit the activity of processed caspase-6 through steric hindrance (42, 43), which disrupts the formation of the active site loop bundle (Figure 3d ) .
Kinase misregulation contributes to HD neuropathology. ARK5, a member of the AMPK family, is a tumor invasion-associated factor downstream of Akt (109) . Interestingly, Akt is responsible for phosphorylation of Htt at Ser421 (110) , which reduces cleavage of Htt by caspase-6 and its nuclear localization and consequently reduces the nuclear accumulation of caspase-6-cleaved Htt fragment (71) . Furthermore, phosphorylation of mHtt at Ser421 is reduced in HD, and phosphorylation of normal Htt at Ser421 is reduced after excitotoxic stimulation of NMDARs (111) . Similarly, total levels of Ser421-phosphorylated mHtt are reduced in the full-length mHtt transgenic YAC128 primary neurons after excitotoxic NMDAR stimulation and YAC128 transgenic mice after quinolinic acid injection into the striatum (111) . In contrast, reduction of phosphorylation of mHtt at Ser421 is prevented in C6R-mHtt YAC128 transgenic mice, which never develop clinical or neuropathological features of HD. These studies suggest (a) that misregulation of kinase pathways contributes to the development of HD and (b) that downregulation of Akt and ARK5 can lead to reduced phosphorylation of mHtt and autoactivation of caspase-6, leading to an increase in the amount of caspase-6-cleaved mHtt fragment.
The Activation and Regulation Model of Caspase-6
Thus far, several structures of caspase-6 in different states or in complex with different inhibitors have been published (11, 42, 43, 107, (112) (113) (114) (115) (116) . On the basis of these structures and related biochemical studies, we summarize the activation and regulation pathways of caspase-6 (Figure 4) . The activation and regulation map of caspase-6. Six states of caspase-6, including full-length zymogen (proCASP6H121A), pro-caspase-6 zymogen ( proCASP6C163A), free active caspase-6, Ac-VEID-CHO-inhibited caspase-6, pseudophosphorylated zymogen ( proCASP6S257E), and pseudophosphorylated activated caspase-6 (p20/p10S257E), are observed in crystal structures, and the PDB IDs of the structures are shown. The seventh structure model is a proposed intermediate. The dashed lines refer to flexible parts that are unobserved in crystal structures. Abbreviation: CASP3, caspase-3; PBD ID, Protein Data Bank identifier.
The pathways contain seven different forms of caspase-6, six of which are seen in crystal structures. The seventh structural model represents a proposed transient intermediate, which shows the TEVD 193 -bound state after it has undergone small conformational changes and is primed for the nucleophilic attack and intramolecular self-cleavage.
The caspase-6 zymogen can be activated in one of two ways: via autoactivation or caspase-3-mediated activation. In the autoactivation process, the prodomain inhibits the self-cleavage when the concentration of caspase-6 is low. The expression of caspase-6 is upregulated by p53 directly (82) . Once p53 upregulates the expression of caspase-6, the concentration of caspase-6 increases, and the prodomain is removed first, after which autoactivation commences. The prodomain inhibits caspase-6 autoactivation but not caspase-3-mediated activation of caspase-6, and this inhibition by the prodomain is effective only at low caspase-6 concentrations.
The pro-caspase-6 zymogen shows the TEVD 193 -bound conformation. The presence of TEVD 193 in the active site inhibits the activation and activity of caspase-6 by competing with substrate and preventing intermolecular cleavage at this site. However, this TEVD 193 -bound state is usually maintained in a so-called standby conformation for intramolecular self-cleavage because the peptide bond between Asp193 and Ala194 is located sufficiently close to the catalytic C163 such that minor (or stochastic) conformational changes may trigger intramolecular autoactivation.
Phosphorylation at Ser257 locks the zymogen in the TEVD 193 -bound state and prevents the intramolecular self-cleavage, whereas dephosphorylation favors autoactivation. If active caspase-3 is in the system, caspase-6 is cleaved by caspase-3 and becomes activated. Phosphorylation cannot prevent caspase-3-mediated cleavage, but it inhibits the activity of caspase-3-activated caspase-6. Autoactivated-or caspase-3-activated unphosphorylated caspase-6 is active and ready to cleave its substrates; however, this kind of active caspase-6 may still be further regulated by caspase inhibitors.
INHIBITORS OF CASPASE-6
Crucial roles for caspase-6 in HD and AD are well documented and established; thus, the mechanisms for activation and regulation of caspase-6 could serve as effective targets for the development of pharmaceutical therapies against these neurodegenerative disorders. The activation and regulation mechanisms for caspase-6 discussed above shed light on the possibility for modulating caspase-6 activity at different levels, and the crystal structures of caspase-6 in different states provide important structural bases for inhibitor design. Developing small molecules that can inhibit caspase-6 specifically is a hot topic for HD and AD research and therapy. In this section, we review and discuss the existing natural and synthetic inhibitors of caspase-6 and strategies for further inhibitor development.
Natural Inhibitors
The natural occurring inhibitors of caspases include cowpox virus product cytokine response modifier A (CrmA), Fas-associated death domain-like interleukin-1-β-converting enzyme-inhibitory proteins (FLIPs), protease inhibitor 9 (PI-9), baculoviral protein p35, and IAPs. Among those inhibitors, only p35 inhibits caspase-6 to some extent. However, p35 is a broad-spectrum caspase inhibitor, which covalently binds and inhibits caspase-1, -3, -6, -7, -8, and -10 (117). So far, only caspase-6b (an alternatively spliced product of the Mch2 gene, also known as Mch2β) has been identified as a natural specific caspase-6 inhibitor (118). However, it inhibits only autoactivation of caspase-6 and has no effect on caspase-6 that has already been activated.
Synthetic Inhibitors
Most reported synthetic caspase inhibitors are peptide-based pseudosubstrates (119) . The selectivity of these inhibitors depends on their sequences and the specificity of the caspases. The substrate binding pockets of caspases are known as S4-S3-S2-S1, which recognize the different tetrapeptide sequences in their substrates. The S1 and S3 pockets are similar among caspases, and the S2 and S4 pockets contribute to substrate specificity (3) . In caspase-6, the L3 and L4 loops are involved in the formation of the S2 and S4 pockets, which dictate the specificity of caspase-6. Notably, the L4 loop is the most diversified loop among the caspases, and only caspase-6 has a cysteine in its L4 loop, Cys264, that is involved in the formation of both the S2 and S4 pockets (11) . Thus, the Cys264 residue can be used as a perfect anchor as part of the tethering method to develop specific and effective inhibitors of caspase-6. The tethering method is a fragment-based drug discovery method that uses disulfide-bond formation to capture fragments that bind to a site of interest; this method requires a cysteine residue near the target site (120) .
However, targeting the substrate binding pockets may not be the best choice for developing specific inhibitors because all the caspases have a similar substrate binding pocket pattern with overlapping substrate specificities. So far, most synthetic caspase-6 inhibitors are also peptide based (121) (122) (123) (124) . Although many studies have been making great efforts to increase the specificity of the inhibitors, peptide-based inhibitors still tend to display lower specificity and may act on more than one caspase target in vivo, especially when they are at high concentrations (125) . Moreover, peptides normally have poor cell penetration properties and are unlikely to fulfill criteria for bioavailability after oral uptake (126) . Nonpeptide inhibitors have been described for caspase-6 (127), but these inhibitors also target the substrate binding pockets of the enzyme.
One alternative option is to target allosteric sites (128) . Stanger and coworkers (107) reported an allosteric peptide that mediates caspase-6 tetramerization and impairs the function of caspase-6 in vitro and in neuronal cells. Allosteric inhibitors binding in the dimer interface have also been reported for caspase-6 (129). Zinc appears to be another allosteric inhibitor of caspase-6 (130), but it inhibits other caspases as well (131) . The phosphorylation-mediated inhibition suggests the phosphorylation site can be used as an alternative site for the development of allosteric inhibitors. In addition to inhibitors that impair active loop bundle formation, small molecules that can lock caspase-6 in the TEVD 193 -bound conformation, which mimics the phosphorylated state, may also work well as allosteric inhibitors. Furthermore, ARK5, the protein kinase that mediates phosphorylation of caspase-6 at Ser257 (see above), can be a potential target as well. ARK5-mediated phosphorylation inhibits both activation and activity of caspase-6, and it also controls the expression level of caspase-6 indirectly because it phosphorylates and suppresses p53 (132) .
Although caspase-6-specific inhibitors have garnered much attention in recent years, their use in the treatment of diseases could be challenging. Because of the wide expression of caspase-6 and the need for drugs that inhibit its activity to access the disease-relevant areas of the brain, caspase-6 inhibitors may not efficiently reach their desired targets and may have undesired effects on healthy tissues/organs. Thus, developing specific caspase-6 inhibitors that can be distributed only to the target site without affecting healthy tissues/organs is a promising direction of future research. The blood-brain barrier is one of the significant obstacles preventing caspase-6-specific inhibitors from reaching the brain, and specialized drug delivery systems are required to get through this barrier and to achieve efficient delivery. Drug molecules that are modified to resemble ligands of expressed receptors at the blood-brain barrier or conjugated to the ligands are being developed by many research groups worldwide, and nanotechnology-based drug delivery (using drug-encapsulating nanoparticles or drug conjugates) has the potential to solve the problems associated with passing through the blood-brain barrier and targeting the disease-relevant areas (133) .
CONCLUSION
Increasing evidence has shown that caspase-6 plays crucial roles in the development of HD and AD. Consequently, activation and regulation of caspase-6 have been considered important targets for the development of pharmaceutical therapies against these neurodegenerative disorders (74, 128) . Structural and biochemical studies of caspase-6 have revealed unique and highly detailed mechanisms of autoactivation by intramolecular self-cleavage, phosphorylation-mediated inhibition, and "suicide protection" of the prodomain during autoactivation. The crystal structures of caspase-6 in different states have provided insight and important structural bases for specific inhibitor design. However, several debatable questions about caspase-6 need to be addressed in the future. Whether caspase-6 is the sole or even the primary caspase leading to HD and AD pathology has not been confirmed in vivo; thus, assays that can specifically and accurately detect the activity of caspases are required. Furthermore, despite the known activation and regulation mechanisms of caspase-6, we still face the crucial question of which signaling pathway stimulates and triggers caspase-6 activation in these neurodegenerative diseases. In addition, the questions of what mediates the translocation of caspase-6 between the nucleus and cytoplasm and how the location of caspase-6 influences its function also need to be addressed.
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